MondegarAI
Finepoint Capital LP

Q2 2024 · 13F-HR

Finepoint Capital LPholdings as filed

Filed 2024-08-13 · accession 0000904454-24-000458

$352.3M
Reported value
25
Positions
2024-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
530307305LBRDKLIBERTY BROADBAND CORP$109.3M31.0%1,994,510CommonSOLE
76155X100RVMDREVOLUTION MEDICINES INC$28.3M8.04%729,464CommonSOLE
04351P101ASNDUSDASCENDIS PHARMA A/S$25.8M7.33%189,272CommonSOLE
85205L107SWTXUSDSPRINGWORKS THERAPEUTICS INC$24.0M6.83%638,352CommonSOLE
04016X101ARGXARGENX SE$23.2M6.60%54,028CommonSOLE
803607100SRPTSAREPTA THERAPEUTICS INC$21.0M5.96%132,835CommonSOLE
61559X104MLTXMOONLAKE IMMUNOTHERAPEUTICS$17.1M4.85%388,835CommonSOLE
04335A105ARVNARVINAS INC$15.3M4.34%574,378CommonSOLE
004225108ACADACADIA PHARMACEUTICALS INC$14.7M4.18%905,384CommonSOLE
89422G107TVTXTRAVERE THERAPEUTICS INC$14.6M4.15%1,776,728CommonSOLE
23282W605CYTKCYTOKINETICS INC$13.9M3.94%256,449CommonSOLE
36315X101LKFTGALAPAGOS NV$13.4M3.82%542,762CommonSOLE
75943R102RLAYRELAY THERAPEUTICS INC$10.5M2.97%1,605,346CommonSOLE
G72800108PRTAPROTHENA CORP PLC$8.9M2.54%433,471CommonSOLE
30233G209EYPTEYEPOINT PHARMACEUTICALS INC$6.2M1.75%707,404CommonSOLE
83422E204SLDBSOLID BIOSCIENCES INC$5.5M1.55%961,251CommonSOLE
17144M110CHURCHILL CAPITAL CORP VII$191,8000.05%548,000CommonSOLE
G6202B119MNYWWMONEYHERO LIMITED$71,6000.02%895,000CommonSOLE
20607U116CNDAWCONCORD ACQUISITION CORP II$44,9170.01%408,333CommonSOLE
G63836111IVCPWSWIFTMERGE ACQUISITION CORP$39,2000.01%490,000CommonSOLE
G9845F117LSBWFLAKESHORE BIOPHARMA CO LTD$33,3690.01%489,999CommonSOLE
320703119CLDWWCALIDI BIOTHERAPEUTICS INC$27,5840.01%655,200CommonSOLE
G2476C123CDAWFCOMPASS DIGITAL ACQUISITION CORP$27,5480.01%459,906CommonSOLE
56608A113MARBLEGATE ACQUISITION CORP$26,8280.01%735,000CommonSOLE
320703101CALIDI BIOTHERAPEUTICS INC$25,0000.01%125,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.